Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
YS Stock Forecast 2026-2027
$0.07
Current Price
$13.18M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to YS Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
YS Price Momentum
-12.5%
1 Week Change
+75.0%
1 Month Change
-93.0%
1 Year Change
-91.7%
Year-to-Date Change
-95.3%
From 52W High of $1.48
+151.8%
From 52W Low of $0.03
📊 TOP ANALYST CALLS
Did YS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ys Biopharma is one of their latest high-conviction picks.
Latest YS Stock Price Targets & Analyst Predictions
YS has shown a year-to-date change of -91.7% and a 1-year change of -93.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for YS. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
YS Analyst Ratings
0
Buy
0
Hold
0
Sell
YS Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.07
Latest YS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for YS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2023 | Noble Capital Markets | Gregory Aurand | Outperform | Initiates | $5.25 |
Ys Biopharma Co Ltd. (YS) Competitors
The following stocks are similar to Ys Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ys Biopharma Co Ltd. (YS) Financial Data
Ys Biopharma Co Ltd. has a market capitalization of $13.18M with a P/E ratio of 0.0x. The company generates $687.20M in trailing twelve-month revenue with a 77.7% profit margin.
Revenue growth is -45.1% quarter-over-quarter, while maintaining an operating margin of -16.5% and return on equity of -38.9%.
Valuation Metrics
Market Cap
$13.18M
Enterprise Value
$141.70M
P/E Ratio
0.0x
PEG Ratio
N/A
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
-45.1%
Gross Margin
+81.9%
Operating Margin
-16.5%
Net Margin
+77.7%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
N/A
Current Ratio
1.4x
Debt/Equity
1.0x
ROE
-38.9%
ROA
-16.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ys Biopharma Co Ltd. (YS) Business Model
About Ys Biopharma Co Ltd.
What They Do
Develops vaccines and therapeutic biologics.
Business Model
The company discovers, develops, manufactures, and commercializes vaccines and therapeutic biologics primarily aimed at infectious diseases and cancer. By leveraging its proprietary PIKA immunomodulating technology platform, it generates revenue through the sale of its products, including specialized vaccines targeting rabies and COVID-19.
Additional Information
Founded in 2002 and headquartered in Beijing, YS Biopharma operates across multiple countries, including the United States, Singapore, the UAE, and the Philippines, indicating a broad market reach and potential for growth in various regions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
773
CEO
Dr. Hui Shao C.F.A., M.B.A., Ph.D.
Country
China
IPO Year
2021
Website
www.ysbiopharm.comYs Biopharma Co Ltd. (YS) Latest News & Analysis
Latest News
Quick Summary
YS Biopharma Co., Ltd. announced news from Gaithersburg, Md., on May 24, 2024. Further details on the announcement were not provided in the excerpt.
Why It Matters
YS Biopharma's news could indicate developments in biotechnology or pharmaceutical advancements, potentially affecting stock performance and market sentiment in related sectors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
YS Biopharma Co., Ltd. announced news from Gaithersburg, Md. on May 21, 2024. Further details were not provided in the excerpt.
Why It Matters
YS Biopharma's developments could impact stock performance and market positioning in the biotech sector, influencing investor sentiment and potential returns.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
YS Biopharma Co., Ltd. announced news from Gaithersburg, Maryland, on May 7, 2024. Further details were not provided in the excerpt.
Why It Matters
YS Biopharma's announcement could indicate developments in biotechnology, impacting stock performance and investor sentiment in the sector. Watch for potential market reactions and opportunities.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
YS Biopharma Co., Ltd. announced news from Gaithersburg, MD, on April 29, 2024. Further details are not provided in the excerpt.
Why It Matters
YS Biopharma's news could signal developments in biotech, impacting stock prices and investor sentiment in the sector. Key announcements may affect future earnings and growth potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
YS Biopharma Co., Ltd. (NASDAQ:YS) will hold its Q3 2024 Earnings Conference Call on April 19, 2024, at 8:00 AM ET, featuring key company executives.
Why It Matters
YS Biopharma's earnings call provides insights into financial performance and strategic direction, critical for assessing growth potential and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
2 years ago
Quick Summary
YS Biopharma Co., Ltd. announced news on April 19, 2024, from Gaithersburg, Maryland. Further details of the announcement were not provided in the excerpt.
Why It Matters
YS Biopharma's news could signal developments in biotech, impacting stock performance and investor confidence in the sector, potentially affecting market trends and investment strategies.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About YS Stock
What is Ys Biopharma Co Ltd.'s (YS) stock forecast for 2026?
Analyst forecasts for Ys Biopharma Co Ltd. (YS) are not currently available. The stock is trading at $0.07.
Is YS stock a good investment in 2026?
Analyst ratings for YS are not currently available. The stock is currently trading at $0.07. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for YS stock?
Price predictions from Wall Street analysts for YS are not currently available. The stock is trading at $0.07.
What is Ys Biopharma Co Ltd.'s business model?
The company discovers, develops, manufactures, and commercializes vaccines and therapeutic biologics primarily aimed at infectious diseases and cancer. By leveraging its proprietary PIKA immunomodulating technology platform, it generates revenue through the sale of its products, including specialized vaccines targeting rabies and COVID-19.
What is the highest forecasted price for YS Ys Biopharma Co Ltd.?
Price targets from Wall Street analysts for YS are not currently available. The stock is trading at $0.07.
What is the lowest forecasted price for YS Ys Biopharma Co Ltd.?
Price targets from Wall Street analysts for YS are not currently available. The stock is trading at $0.07.
What is the overall YS consensus from analysts for Ys Biopharma Co Ltd.?
Analyst ratings for YS are not currently available. The stock is trading at $0.07.
How accurate are YS stock price projections?
Stock price projections, including those for Ys Biopharma Co Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 8:01 PM UTC